Sanofi Oncology Strategy: A New Lease On Cancer R&D
This article was originally published in Scrip
After failing to transition its cancer portfolio from chemotherapy to targeted cancer drugs, Sanofi is recharging its cancer strategy, relying on a collaboration with Regeneron Pharmaceuticals Inc. to vault it into the hot field of immuno-oncology.
You may also be interested in...
The US company is encouraged by top-line efficacy Phase III results showing pacritinib was effective in high-risk myelofibrosis patients with low platelet counts, and has said it is working with the FDA to lift the clinical hold imposed earlier this year because of side-effect concerns.
The dermatology specialist said a BLA for the IL-13 blocker has been accepted by the US FDA for the treatment of atopic dermatitis.
Kymera will receive $150m upfront from Sanofi in a deal the big pharma views as an opportunity to develop a breakthrough oral drug for atopic dermatitis and other conditions.